{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-005310","form_type":"8-K","ticker":"AIM","cik":"0000946644","company_name":"AIM ImmunoTech Inc.","filed_at":"2025-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.907656+00:00","generated_at":"2026-05-27T01:18:07.032723+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aim ImmunoTech plans combo study of Ampligen and FluMist for avian flu","bullets":["Plans to file IND for trial combining Ampligen with AstraZeneca's FluMist to target avian influenza.","Prior UAB clinical data showed Ampligen + FluMist induced cross-reactive antibodies against H5N1, H7N9, H7N3.","Pre-clinical work demonstrated 50-100% survival in mice challenged with H5N1 variants vs. 0-60% naive controls.","AIM has engaged CRO Amarex for IND application and study management; seeking government/industry grants."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-005310","json":"https://secwatch.observer/filing/0001493152-25-005310.json","markdown":"https://secwatch.observer/filing/0001493152-25-005310.md","text":"https://secwatch.observer/filing/0001493152-25-005310.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946644/000149315225005310/0001493152-25-005310-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946644/000149315225005310/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T01:18:07.032723+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}